Elizabeth R. Volkmann, MD, MS

Elizabeth R. Volkmann, MD, MS

Rheumatology
Accepting new patients
Primary Location
Westwood Specialty Care
200 Medical Plaza
Suite 365
Los Angeles, California 90095
Phone
Fax
310-825-5105

About

Dr. Elizabeth Volkmann is the Director of the UCLA Scleroderma Program and the founder and Co-Director of the UCLA Connective Tissue Disease-Related Interstitial Lung Disease (CTD-ILD) Program. She is an internationally recognized expert in systemic sclerosis and connective tissue disease-related interstitial lung disease.

Board-certified in both Internal Medicine and Rheumatology, Dr. Volkmann graduated from Pomona College where she majored in Neuroscience and minored in Dance. She received her medical degree from UCLA David Geffen School of Medicine, and subsequently completed her residency in Internal Medicine and fellowship in Rheumatology at UCLA. During her fellowship, she participated in the Specialty Training and Advanced Research (STAR) Program and earned her Master of Science degree in Clinical Research.

Dr. Volkmann cares deeply about the welfare of her patients and seeks to empower them on their healing journey with traditional, as well as holistic treatment approaches. She works closely with other specialists to develop comprehensive and personalized care plans that are unique for each patient.

Dr. Volkmann is also an active clinical and translational researcher in systemic sclerosis and interstitial lung disease. Her research focuses on discovering novel biomarkers that can be used to predict whether someone will improve on a specific therapy. She pioneered the first study to investigate the gut microbiome in patients with systemic sclerosis and now leads an international consortium of investigators dedicated to understanding how the gut microbiome contributes to inflammation and clinical symptoms in patients with systemic sclerosis. She also participates in clinical trials to help identify new therapies for patients with autoimmune diseases.

She enjoys being active in nature (running, hiking, swimming, riding horses), and she loves to travel, dance and spend time with her family and friends.

Patient Stories

Languages

English

Education

Medical Board Certifications

Rheumatology, American Board of Internal Medicine, 2014
Internal Medicine, American Board of Internal Medicine, 2013

Fellowship

UCLA School of Medicine, 2014

Residency

UCLA School of Medicine, 2011

Internship

UCLA School of Medicine, 2010

Degrees

UCLA School of Medicine, MS, 2014
UCLA School of Medicine, MD, 2008

Recognitions

Hospital Affiliations

Ronald Reagan UCLA Medical Center

UCLA Santa Monica Medical Center

Areas of Focus

Pulmonary hypertension associated connective tissue disease
Pulmonary fibrosis
Interstitial lung disease
Systemic scleroderma
Localized scleroderma
Scleroderma

Research

Interests

  • Systemic Sclerosis
  • Interstitial Lung Disease
  • Pulmonary Hypertension
  • Microbiome

Publications

Link to Dr. Volkmann's PubMed publications

Selected publications

  1. Volkmann ER, Tashkin DP, Silver R, et al. Sex differences in biologic profiles and clinical outcomes in two randomized controlled trials for systemic sclerosis-related interstitial lung disease. Lancet Rheumatology 2022;4:E668-78.

  2. Volkmann ER, Tashkin DP, Roth MD, et al. Early radiographic progression of scleroderma lung disease predicts long-term mortality. Chest 2022;161:1310-9.

  3. Volkmann ER, Steen VD, Li N, Roth MD, et al. Racial disparities in systemic sclerosis: Short- and long-term morbidity and mortality outcomes of African American participants of SLS I and II. ACR Open Rheumatology 2020;3:8-16.
  4. Volkmann ER, Hoffmann-Vold A-M, Chang Y-L, et al. Longitudinal characterisation of the gastrointestinal tract microbiome in systemic sclerosis.  EMJ 2020;5:110-8.
  5. Volkmann ER, Tashkin DP, Sim M, et al. Early progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. Annals of Rheumatic Diseases 2019;78:122-30.
  6. Volkmann ER, Tashkin DP, Kuwana M, et al. Progression of interstitial lung disease in systemic sclerosis: The importance of pneumoproteins KL-6 and CCL-18. Arthritis and Rheumatology 2019;71:2059-67.
  7. Volkmann ER, Varga J. Emerging treatments for systemic sclerosis. Nature Rev Rheumatology 2019;15:208-24.
  8. Volkmann ER, Tashkin DP, Sim M, et al. Cyclophosphamide for systemic sclerosis-related interstitial lung disease: A comparison of Scleroderma Lung Studies I and II. Journal of Rheumatology 2019;46:1316-25.
  9. Volkmann ER, Tashkin DP, Li N, et al. Mycophenolate versus placebo for patients with systemic sclerosis-related interstitial lung disease. Arthritis and Rheumatol 2017;69:1451-60.
  10. Volkmann ER, Hoffmann-Vold A-M, Chang Y-L, et al. The systemic sclerosis disease state is associated with specific alterations in gastrointestinal microbiota in two independent cohorts. BMJ Gastroenterology 2017;4e000134.

 

Recognitions

  • Doctor of the Year, National Scleroderma Foudation, 2022
  • Southern California Rising Stars, Super Doctors®, 2022
  • Top Doctors, Los Angeles Magazine, 2021
  • Southern California Rising Stars, Super Doctors®, 2021
  • Edith Busch-Stiftung Award in Rheumatology, 2020
  • Southern California Rising Stars, Super Doctors®, 2020
  • Southern California Rising Stars, Super Doctors®, 2019